Canada · Delayed Price · Currency is CAD MediPharm Labs Statistics
Total Valuation
MediPharm Labs has a market cap or net worth of CAD 29.74 million. The enterprise value is 19.41 million.
| Market Cap | 29.74M |
| Enterprise Value | 19.41M |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MediPharm Labs has 424.86 million shares outstanding. The number of shares has increased by 2.41% in one year.
| Current Share Class | 424.86M |
| Shares Outstanding | 424.86M |
| Shares Change (YoY) | +2.41% |
| Shares Change (QoQ) | +0.75% |
| Owned by Insiders (%) | 9.16% |
| Owned by Institutions (%) | 0.00% |
| Float | 385.94M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.69 |
| PB Ratio | 0.85 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.02, with a Debt / Equity ratio of 0.00.
| Current Ratio | 3.02 |
| Quick Ratio | 1.98 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | -125.39 |
Financial Efficiency
Return on equity (ROE) is -22.33% and return on invested capital (ROIC) is -30.83%.
| Return on Equity (ROE) | -22.33% |
| Return on Assets (ROA) | -10.16% |
| Return on Invested Capital (ROIC) | -30.83% |
| Return on Capital Employed (ROCE) | -22.15% |
| Weighted Average Cost of Capital (WACC) | 9.33% |
| Revenue Per Employee | 340,795 |
| Profits Per Employee | -68,874 |
| Employee Count | 127 |
| Asset Turnover | 0.90 |
| Inventory Turnover | 3.27 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.25% in the last 52 weeks. The beta is 0.89, so MediPharm Labs's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -6.25% |
| 50-Day Moving Average | 0.08 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 48.20 |
| Average Volume (20 Days) | 204,454 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediPharm Labs had revenue of CAD 43.28 million and -8.75 million in losses. Loss per share was -0.02.
| Revenue | 43.28M |
| Gross Profit | 12.54M |
| Operating Income | -7.77M |
| Pretax Income | -8.75M |
| Net Income | -8.75M |
| EBITDA | -6.20M |
| EBIT | -7.77M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 10.35 million in cash and 18,000 in debt, with a net cash position of 10.33 million or 0.02 per share.
| Cash & Cash Equivalents | 10.35M |
| Total Debt | 18,000 |
| Net Cash | 10.33M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 35.10M |
| Book Value Per Share | 0.08 |
| Working Capital | 17.21M |
Cash Flow
In the last 12 months, operating cash flow was -3.32 million and capital expenditures -59,000, giving a free cash flow of -3.38 million.
| Operating Cash Flow | -3.32M |
| Capital Expenditures | -59,000 |
| Depreciation & Amortization | 1.58M |
| Net Borrowing | -111,000 |
| Free Cash Flow | -3.38M |
| FCF Per Share | -0.01 |
Margins
Gross margin is 28.96%, with operating and profit margins of -17.96% and -20.21%.
| Gross Margin | 28.96% |
| Operating Margin | -17.96% |
| Pretax Margin | -20.21% |
| Profit Margin | -20.21% |
| EBITDA Margin | -14.33% |
| EBIT Margin | -17.96% |
| FCF Margin | n/a |
Dividends & Yields
MediPharm Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.41% |
| Shareholder Yield | -2.41% |
| Earnings Yield | -29.41% |
| FCF Yield | -11.35% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediPharm Labs has an Altman Z-Score of -2.42 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.42 |
| Piotroski F-Score | 2 |